Prognostication in primary myelofibrosis

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 43-49

  Cervantes, Francisco ^a   Pereira, Arturo ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Disease; Myelofibrosis with myeloid metaplasia; Myeloproliferative neoplasms; Primary myelofibrosis; Prognosis; Prognostic factors; Survival

Indexed keywords

HEMOGLOBIN; INTERLEUKIN 2; INTERLEUKIN 8;

ACUTE LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CYTOGENETICS; DISEASE COURSE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTOSIS; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; PALLIATIVE THERAPY; PATHOGENESIS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; THROMBOCYTOPENIA; TREATMENT INDICATION; WEIGHT REDUCTION; AGE; CELL TRANSFORMATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MORTALITY; MYELOID METAPLASIA; PATHOLOGY; THROMBOCYTE COUNT;

AGE FACTORS; ANEMIA; CELL TRANSFORMATION, NEOPLASTIC; CYTOGENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; PLATELET COUNT; PRIMARY MYELOFIBROSIS; PROGNOSIS; RISK ASSESSMENT;

EID: 84859228045     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0102-1     Document Type: Article

References (44)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;30(114):937-51.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128-38.
3. Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18:117-23.
4. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723-35.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895-901. Based on more than 1,000 PMF patients from several European and American centers, this study by the IWG-MRT defined the first International Prognostic Scoring System (IPSS) for primary myelofibrosis. The IPSS demonstrated high discriminating power and predictive accuracy, and could be reproduced after discounting the demographic factors related to the patients' age, sex, period of diagnosis, and country of origin.
6. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-65. (Pubitemid 30235956)
7. Tefferi A. How I treat myelofibrosis. Blood. 2011;117:3494-504.
8. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis:analysis based on 334 patients from a single institution. Cancer. 2007;109:2083-8. (Pubitemid 46744203)
9. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood. 2010;115:4350-5. These authors rely on competing risk analysis to investigate factors predicting leukemic transformation in PMF.
10. Gangat N, Caramazza D, Vaidya R. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol.2011;29:392-7. These authors show that thrombocytopenia, transfusion need, and some definite cytogenetic abnormalities allow further refinement of the DIPSS.
11. Vaidya R, Siragusa S, Huang J, et al. Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc. 2009;84:1114-9.
12. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905-14. (Pubitemid 351698623)
13. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathicmyelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102. (Pubitemid 27348801)
14. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-8. (Pubitemid 26333326)
15. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703-8. This study builds on previous research by the IWG-MRT to show how the acquisition of the IPSS poor prognosis factors during the course of PMF (dynamic IPSS or DIPSS) allows dynamic prediction of the patients' remaining lifeexpectancy.
16. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-40. (Pubitemid 27261631)
17. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-90. (Pubitemid 28387050)
18. Barosi G, Berzuini C, Liberato LN, et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397-401. (Pubitemid 19012570)
19. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9. (Pubitemid 20157973)
20. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognosticin Primary Myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356-63.
21. Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009;84:265-7.
22. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010;85:14-7.
23. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusiondependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96:167-70.
24. Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol. 2011;86:245-50.
25. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34 + cells inmyelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-55.
26. Sagaster V, Jager E, Weltermann A, et al. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia. Haematologica. 2003;88:1204-12. (Pubitemid 37456375)
27. Arora B, Sirhan S, Hover JD, et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2004;128:42-8.
28. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasma. Blood. 2000;96:3374-80.
29. Pereira A, Cervantes F, Brugues R, Rozman C. Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol. 1990;44:95-9. (Pubitemid 20172160)
30. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis:applicability at the time of diagnosis and later during disease course. Blood. 2009;113:4171-8.
31. Hidaka T, Slide K, Shimoda H, et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol. 2009;83:328-33.
32. Hussein K, Pardanani AD, Van Dyke DL, et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115:496-9.
33. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25;82-8. Until now, this is the largest study on the prognostic significance of karyotype abnormalities in PMF.
34. Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-71. (Pubitemid 32524401)
35. Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117:5612-5. This study identifies monosomal karyotype, which is present in about 2% of PMF patients, as a strong predictor of extremely short survival and high risk of leukemic transformation.
36. Santos FPS, Verstovsek S. JAK2 inhibitors: what's the true potential? Blood Rev. 2011;25:53-63.
37. Campbell PJ, Griesshammer M, Döhner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098-100. (Pubitemid 43289395)
38. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:430-6.
39. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756-61. (Pubitemid 351559282)
40. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based onthe burden of JAK2V617F mutated allele. Blood. 2009;114:1477-83.
41. Huang J, Li C-Y Li, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112:2726-32. (Pubitemid 351969217)
42. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587-93.
43. Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients Leukemia. 2011 Jun 21 (Epub ahead of print). doi:10.1038/leu.2011. 161
44. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91:3630-6. (Pubitemid 28225729)